Using exome sequencing, we identify SERAC1 mutations as the cause of MEGDEL syndrome, a recessive disorder of dystonia and deafness with Leigh-like syndrome, impaired oxidative phosphorylation and 3-methylglutaconic aciduria. We localized SERAC1 at the interface between the mitochondria and the endoplasmic reticulum in the mitochondria-associated membrane fraction that is essential for phospholipid exchange. A phospholipid analysis in patient fibroblasts showed elevated concentrations of phosphatidylglycerol-34:1 (where the species nomenclature denotes the number of carbon atoms in the two acyl chains:number of double bonds in the two acyl groups) and decreased concentrations of phosphatidylglycerol-36:1 species, resulting in an altered cardiolipin subspecies composition. We also detected low concentrations of bis(monoacyl-glycerol)-phosphate, leading to the accumulation of free cholesterol, as shown by abnormal filipin staining. Complementation of patient fibroblasts with wild-type human SERAC1 by lentiviral infection led to a decrease and partial normalization of the mean ratio of phosphatidylglycerol-34:1 to phosphatidylglycerol-36:1. Our data identify SERAC1 as a key player in the phosphatidylglycerol remodeling that is essential for both mitochondrial function and intracellular cholesterol trafficking.
The lipid bilayer surrounding cells and organelles consists mainly of phospholipids, such as the common phospholipids phosphatidyl choline and phosphatidylethanolamine and also the less abundant specialized phospholipids cardiolipin and bis(monoacylglycerol)phos phate (Fig. 1a) . Bis(monoacylglycerol)phosphate and cardiolipin are both synthesized from phosphatidylglycerol, which is made de novo in mitochondria 1,2 . Bis(monoacylglycerol)phosphate is an anionic phos pholipid that is necessary for intracellular cholesterol trafficking 3 .
Cardiolipin is essential for the stability and catalytic activity of mito chondrial membrane proteins and is key for apoptosis 4, 5 . Abnormal cardiolipin acyl chain composition and accumulation of monolysocar diolipins results in Barth syndrome (MIM# 302060) 6 , a 3methylgluta conic aciduria (3MGAuria) with (cardio)myopathy, neutropenia and oxidative phosphorylation (OXPHOS) dysfunction 7, 8 . Barth syndrome is caused by mutations in TAZ, which encodes tafazzin, a transacylase that is required for cardiolipin remodeling 9 . Here we identify the causative genetic defect in 15 individuals with MEGDEL syndrome (Supplementary Note), which we have previously defined as 3MGAuria with impaired OXPHOS, deafness, encephalopathy, Leighlike magnetic resonance imaging (MRI), progressive spasticity and dystonia 10, 11 .
MEGDEL syndrome was predicted to be an autosomal recessive dis order based on its occurrence in one large pedigree with two affected siblings (patients 6 and 7) and an affected first cousin (patient 3) and in several individuals from consanguineous families (Supplementary Table 1 ). To find the underlying genetic cause of the syndrome, we sequenced the exomes (~21,000 genes) of two affected individu als using the SureSelect 50 Mb human exome kit and a multiplexed sequence analysis on a SOLiD 4 system. For this analysis, we selected the affected cousin (patient 3) and an unrelated subject (patient 5), who is the affected child of a consanguineous marriage. We applied several filtering steps in which we excluded all nongenic, intronic and synonymous variants, other than those occurring at canonical splice sites, and focused on variants not reported in dbSNP or found in inhouse-sequenced exomes under the assumption of an autosomal recessive inheritance pattern 12 . Only a single gene, SERAC1 (NM_ 032861.3), contained homozygous variants in both affected individuals (Supplementary Table 2 ). For patient 3, 73 of 74 (99%) reads showed a C>T transition at chromosome 6 (hg19):g.158,567,859 indicating Mutations in the phospholipid remodeling gene SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness a homozygous r.442C>U transition at the mRNA level that is pre dicted to result in a premature stop codon (p.Arg148X; Supplementary  Fig. 1) . Similarly, for patient 5, 50 of 52 (96%) reads showed a G>C substitution at chromosome 6 (hg19):g.158,538,758 in the canonical donor splice site of exon 13. Of note, both mutations were located in homozygous regions of size 5.8 Mb and 9.7 Mb, respectively, as shown by homozygosity mapping using 250K arrays (Supplementary Table 3 ). Conventional Sanger sequencing confirmed the presence of these mutations as well as their homozygous state in patients 3 and 5 and in the two cousins of patient 3. We identified neither of these two mutations in 369 healthy ethnically matched controls.
An analysis of the protein coding sequence of SERAC1 in 11 addi tional unrelated individuals clinically diagnosed with MEGDEL syndrome identified 12 additional homo zygous and compound heterozygous mut ations that were absent in 369 healthy ethnically matched controls. In total, we iden tified 14 different mutations in 15 affected individuals from 13 families, including three nonsense, three canonical splice site, four frameshift and three missense mutations and one inframe deletion of a single amino acid ( Table 1, Fig. 1b, Supplementary Table 4 and Supplementary Note). We found the two canonical splice site mutations in exons 13 and 16 and the missense mutation in exon 14 (c.1493G>C) in two, three and two unre lated subjects, respectively, indicating com mon ancestry, which was confirmed by their matching haplotypes ( Supplementary Fig. 2 and Supplementary Note). In addition, an mRNA transcript analysis showed that the exon 13 splice site mutations resulted in skip ping of this exon (Supplementary Fig. 3 ). Eight mutations resulted in a premature termination codon more than 55 nt before the last exonexon boundary and, hence, should give rise to nonsensemediated decay of the SERAC1 mRNA. Indeed, a quantita tive PCR analysis of SERAC1 mRNA levels in fibroblasts from patients 3 and 5 showed 12% (P < 0.0001) and 40% (P < 0.029) of the SERAC1 levels in control fibroblasts, respectively ( Supplementary Fig. 4 and Supplementary Note).
SERAC1 (serine active site containing 1) encodes a protein with a serinelipase domain that is a member of the PGAPlike protein domain family (PFAM PF07819). Nothing is known about the function of this protein, although the presence of a conserved lipase domain containing the consensus lipase motif GXSXG 13 strongly suggests a function in lipid metabolism. SERAC1 is present in all eukaryotes and is highly conserved, espe cially its lipase domain (Supplementary Table 5 and Supplementary Fig. 5 ). The three amino acids (Gly401, Gly404 and Ser498) affected by the missense muta tions and Leu479, which was deleted in one affected individual, are all located within this lipase domain and are fully conserved down to the fruit fly ( Fig. 1b and Supplementary Fig. 5 ). Both the SIFT and PolyPhen2 programs 14, 15 predict these changes to be detrimental to protein func tion. Moreover, Ser498 is the serine of the consensus lipase motif GXSXG (Supplementary Fig. 5 ) 13 .
Barth and MEGDEL syndromes share 3MGAuria and mito chondrial dysfunction. This, in combination with the presence of a lipase domain in SERAC1, formed the rationale for our phospholipid analysis in MEGDEL fibroblasts (Fig. 2) . The concentrations and acyl chain compositions of the major phospholipid classes (phos phatidylcholine, phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol; data not shown) were normal. However, we found higher concentrations of phosphatidylglycerol34:1 l e t t e r s and lower concentrations of phosphatidylglycerol36:1 species in all five affected individuals analyzed as compared to ten control fibroblast cell lines (Fig. 2a,b) . A more detailed analysis of the mass spectrometry fragmentation spectra of phosphatidylglycerol34:1 and phosphatidylglycerol36:1 showed that the most abundant species of these phosphatidylglycerol molecules corresponded to 1palmitoyl(16:0)2oleoyl(18:1) phosphatidylglycerol and 1stearoyl(18:0)2oleoyl(18:1) phosphatidylglycerol ( Supplementary  Fig. 6a ). The median phosphatidylglycerol34:1 concentration in patient fibroblasts was 220% of that in control fibroblasts, whereas the median phosphatidylglycerol36:1 concentration in patient cells was 20% of that in control fibroblasts, resulting in a mean ratio of phosphatidylglycerol34:1 to phosphati dylglycerol36:1 of 8.4 in patient fibroblasts as compared to 0.7 in control fibroblasts, justifying this ratio as a clinically relevant diagnostic marker (Fig. 2b) .
In contrast to individuals with Barth syn drome, the total concentrations of cardiolipin were unaltered in fibroblasts from patients with MEGDEL syndrome (Fig. 2b) . However, there were differences in cardiolipin species composition in the patient fibroblasts com pared to the control fibroblasts. Patients with MEGDEL syndrome had significantly higher concentrations of cardiolipin66:3, cardioli pin66:4, cardiolipin68:3, cardiolipin68:4 and cardiolipin68:5 (Fig. 3) , which are derived from phosphatidylglycerol34:1, than control individuals, whereas other cardioli pin species were the same between the two groups ( Supplementary Fig. 7) . The inability to convert phosphatidyl glycerol34:1 to phosphatidylglycerol36:1 leads to the accumulation of phosphatidylglycerol34:1 and subsequent incorporation into car diolipin. In Barth syndrome, it is firmly established that cardiolipin alterations lead to OXPHOS dysfunction through different mecha nisms, for example, by affecting the stability and assembly of inner mitochondrial membrane respiratory chain complexes 6 . Therefore, the alteration in the concentrations of cardiolipin species is probably directly related to the OXPHOS dysfunction present in different tis sues of patients with MEGDEL syndrome (Supplementary Tables 1  and 6 ). It is of note that the OXPHOS abnormalities in MEGDEL syndrome seem less pronounced than those in Barth syndrome, which VOLUME 44 | NUMBER 7 | JULY 2012 Nature GeNetics l e t t e r s may relate to the substantial differences in total cardiolipin content between the two diseases and the fact that monolysocardiolipins accu mulate in Barth syndrome but are normal in patients with MEGDEL syndrome. Morphologically, however, we found an aggregation of degrading mitochondria in the muscle of patients with MEGDEL syn drome using electron microscopy ( Supplementary Fig. 8 ). We evalu ated autophagy and mitophagy under basal conditions and under induced cellular stress in fibroblasts by analyzing the concentrations of mitochondrial marker proteins (GRP75 and MTCO2) and autophagy and mitophagy marker proteins (LC3, Mfn2, P62 and Parkin) and found no differences between patients and controls ( Supplementary  Fig. 9 and Supplementary Note). Mitochondrial fusion and fission were also normal in patients with MEGDEL syndrome, as evidenced by semiquantitative immunohistochemistry and a quantitative PCR analysis of the fusion and fission protein markers Fis1, Drp1, Opa1 and Mfn1 ( Supplementary Fig. 10 and Supplementary Note).
Besides changes in phosphatidylglycerol and cardiolipin species composition, the median bis(monoacylglycerol)phosphate concen tration in patients was 40% of that in controls (Fig. 2b) . The four most abundant bis(monoacylglycerol)phosphate species (34:1, 36:2, 40:7 and 44:12) had identical acyl chain composition in patients and controls (Supplementary Fig. 6b ). Low bis(monoacylglycerol)phos phate concentrations are known to lead to free cholesterol accumula tion in late endosomes 16 . We assessed the accumulation of unesterified cholesterol in patient and control fibroblasts. For comparison, we used NiemannPick type C (NPC) fibroblasts, which are known to accu mulate unesterified cholesterol 17 . All three patients with MEGDEL syndrome tested clearly had more filipin staining than the control (Fig. 2c) . In general, the localization of the fluorescent signal seemed more prominent in the perinuclear region of the MEGDEL fibroblasts as compared to the NPC fibroblasts, which showed an abundance of small aggregates with positive fluorescence throughout the cell. These results suggest an accumulation of unesterified cholesterol in patients with MEGDEL syndrome. This conclusion is supported by the lipid storage found in the muscle of patients with MEGDEL syndrome (Supplementary Fig. 8) . Because intracellular accumulation of cholesterol may lead to lower blood cholesterol concentrations, we reinvestigated all subjects with mutations in SERAC1. Notably, 4 of 11 patients with MEGDEL syndrome in whom cholesterol was measured had a cholesterol concentration below the lower reference range limit, but for the total group of 11 patients in this study, the serum cholesterol concentrations were not statistically different from controls (Supplementary Table 1) .
SERAC1 is ubiquitously expressed, with markedly high expres sion in fetal muscle and in adult brain ( Supplementary Fig. 11 and Supplementary Note). Prediction of the subcellular localization of SERAC1 by PSORT II suggested a mitochondrial localization (a 43.5% chance of mitochondrial localization compared to a 30.4% chance npg l e t t e r s of cytosolic localization and an 8.7% chance of nuclear localization). Accordingly, a western blot analysis showed that SERAC1 was absent from the cytosol (Fig. 4a) but was enriched in the crude mitochon drial and endoplasmic reticulum (ER) fractions compared to total cell lysates (Fig. 4a,b and Supplementary Note). Subsequent treat ment of crude mitochondrial fractions with proteinase K showed that the amount of SERAC1 decreased, whereas the outer mitochondrial membrane protein marker TOM20 was fully degraded (Fig. 4c) . However, calnexin, an ER marker protein that is enriched in the mitochondriaassociated membranes (MAMs) 18 that copurify with the crude mitochondrial fraction 19 , showed a similarly confined pro tection pattern as SERAC1 after proteinase K treatment. This finding, together with the SERAC1 enrichment in the ER (Fig. 4b) , suggests that SERAC1 localizes at the ER and at the ERmitochondria interface. This is supported by immunohistological studies in which SERAC1 was found in close proximity to the mitochondria but only partially colocalized with the mitochondrial matrix protein MRPL12 (Fig. 4d) .
In addition, the difference in the mean ratio of phosphatidylglycerol 34:1 to phosphatidylglycerol36:1 between patients and controls was more evident in the crude mitochondrial fraction compared to in the total fibroblasts (19.3 compared to 8.4, respectively; Fig. 4e ). This indicates that phosphatidylglycerol remodeling probably occurs in this fraction, which is in line with the proposed intracellular locali zation of SERAC1 at the interface of the two compartments and the fact that the exchange of phospholipids has been shown to be a key function of the MAM 20 . The localization of SERAC1 at the contact sites between the ER and mitochondria, the low concentrations of phosphatidylglycerol36:1 and the accumulation of phosphatidylglycerol34:1 in MEGDEL fibroblasts indicate that SERAC1 catalyzes the remodeling of phos phatidylglycerol and is involved in the transacylationacylation reaction to produce phosphatidylglycerol36:1. The altered acyl chain composition of the affected phosphatidylglycerol molecules suggests that SERAC1 catalyzes the transfer of stearic acid (18:0) from an as yet unknown donor to 1palmitoyl(16:0)2oleoyl(18:1) phosphatidylglycerol to produce 1stearoyl(18:0)2oleoyl(18:1) phosphatidylglycerol and, thus, effectively exchanges palmitic acid (16:0) on the sn1 position of phosphatidylglycerol34:1 for stearic acid (18:0). We postulate that phosphatidylglycerol34:1 is the primary precursor of bis(monoacylglycerol)phosphate species and that the inability to produce phosphatidylglycerol36:1 from phosphatidylglycerol34:1 causes bis(monoacylglycerol)phosphate deficiency (Fig. 2d) . To support this role of SERAC1 in phosphati dylglycerol remodeling, we successfully complemented two patient fibroblast lines with wildtype human SERAC1 by lentiviral infection, which led to a decrease and partial normalization of the mean ratio of phosphatidylglycerol34:1 to phosphatidylglycerol36:1 from 8.6 to 4.0 (Fig. 5) , directly linking mutations in SERAC1 to compromised phosphatidylglycerol remodeling. We found no differences in the concentrations and subspecies distribution of other phospholipids (phosphatidylcholine, phosphatidylethanolamine and phosphatidyl serine; Supplementary Fig. 12 ).
In conclusion, mutations in SERAC1 cause a clinically recognizable progressive neurological deafness dystonia syndrome (MEGDEL). MEGDEL syndrome is a phospholipid remodeling disorder, but it also classifies as a defect in intracellular cholesterol trafficking. Our data identify SERAC1, a protein located at the contact sites between mitochondria and the ER, as a key player in the remodeling of phosphatidylglycerol, particularly of those species needed for the synthesis of bis(monoacylglycerol)phosphate. SERAC1 is crucial for both mitochondrial function and intracellular cholesterol trafficking.
This study identifies SERAC1 as catalyzing the first enzymatic reaction in the as yet unknown bis(monoacylglycerol)phosphate bio synthetic pathway.
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Methods and any associated references are available in the online version of the paper. streptomycin (100 µg/ml)) and 2 µg/ml blasticidin (InvivoGen). Cells were selected for 14 d, in which time the mockinfected cells (without virus) died. Blasticidinresistant cells were used for biochemical analysis within 6 passages after transduction.
